Atrial fibrillation (AF) is the most common arrhythmia worldwide, afflicting patients’ prognosis and symptoms. The European Heart Rhythm Association (EHRA) proposed the EHRA score for grading the impact of AF symptoms on daily patients’ quality of life, from I (no symptoms) to IV (disabling symptoms) and this grading has been implemented into consensus guidelines [1]. Worldwide, an important proportion of patients have AF without symptoms [2,3]. In a recent large meta-analysis, the association of mortality and stroke/thromboembolism (TE) between asymptomatic and symptomatic AF patients was similar [4].
